Abstract
Protein kinase B (PKB or Akt) is a central component of the PI3K – PKB – mTOR signalling cascade and is firmly established as an attractive target for pharmacological intervention in cancer. A number of small molecule inhibitors with well-defined, direct molecular interactions with PKB are now known, covering a range of mechanisms from ATP- or substrate-competitive inhibition, through allosteric modulation of the kinase activity, to inhibition of the phosphatidylinositol-dependent activation process. The development of small molecule inhibitors of PKB has benefited greatly from the application of structural biology techniques, particularly for lead generation and the optimisation of compound potency and selectivity. The development of the major chemical series of PKB inhibitors will be outlined, with an emphasis on the application of structure-based design and the strategies used to optimise compound pharmacodynamics, efficacy and therapeutic window. The development of small molecules targeting PKB for anticancer therapy has reached an exciting stage, with the first selective inhibitors entering clinical trials, and several additional chemotypes demonstrating efficacy in preclinical models.
Keywords: Protein kinase B, Akt, inhibitors, anticancer agents, structure-based design
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents
Volume: 9 Issue: 1
Author(s): Ian Collins
Affiliation:
Keywords: Protein kinase B, Akt, inhibitors, anticancer agents, structure-based design
Abstract: Protein kinase B (PKB or Akt) is a central component of the PI3K – PKB – mTOR signalling cascade and is firmly established as an attractive target for pharmacological intervention in cancer. A number of small molecule inhibitors with well-defined, direct molecular interactions with PKB are now known, covering a range of mechanisms from ATP- or substrate-competitive inhibition, through allosteric modulation of the kinase activity, to inhibition of the phosphatidylinositol-dependent activation process. The development of small molecule inhibitors of PKB has benefited greatly from the application of structural biology techniques, particularly for lead generation and the optimisation of compound potency and selectivity. The development of the major chemical series of PKB inhibitors will be outlined, with an emphasis on the application of structure-based design and the strategies used to optimise compound pharmacodynamics, efficacy and therapeutic window. The development of small molecules targeting PKB for anticancer therapy has reached an exciting stage, with the first selective inhibitors entering clinical trials, and several additional chemotypes demonstrating efficacy in preclinical models.
Export Options
About this article
Cite this article as:
Collins Ian, Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152009787047734
DOI https://dx.doi.org/10.2174/187152009787047734 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone
Anti-Cancer Agents in Medicinal Chemistry Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Renal and Hepatic Kinetics of Tc-99m-labelled Hexakis-methoxy-isobutyl Isonitrile
Drug Metabolism Letters The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Inducible Nitric Oxide Synthase Expression is a Potential Marker for Acute Coronary Syndrome: A Preliminary Study
Current Biomarkers (Discontinued) Challenges and Opportunities for Clinical Research in the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Antitumour Activity of Muricatacin Isomers and its Derivatives in Human Colorectal Carcinoma Cell HCT116
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science Mistletoe and Garlic Extracts as Polyurethane Carriers – A Possible Remedy for Choroidal Melanoma
Current Drug Delivery Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials An Optimized Approach for Breast Cancer Classification for Histopathological Images Based on Hybrid Feature Set
Current Medical Imaging On the Role of Rab5 in Cell Migration
Current Molecular Medicine Recent Developments on Organo-bicyclo-bases Catalyzed Multicomponent Synthesis of Biologically Relevant Heterocycles
Current Organic Chemistry Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets